Sian Bigora
About Sian Bigora
Sian Bigora, Pharm.D., age 64, is Processa Pharmaceuticals’ Chief Development and Regulatory Officer (since Oct 4, 2017), with 30+ years in regulatory strategy, pharmacovigilance, and late-stage development; she holds a Pharm.D. from University of Maryland and completed a fellowship in Pharmacokinetics & Pediatric Infectious Diseases there . Under her tenure, the company’s TSR has declined materially (value of $100 investment: $74→$17→$5→$1 for 2021–2024) alongside persistent net losses, highlighting execution risk in translating R&D milestones to shareholder returns . Notable operational achievements tied to compensation include regaining Nasdaq minimum price compliance and dosing the first patient in the NGC‑Cap Phase 2 trial in 2024 .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Questcor Pharmaceuticals | Vice President, Regulatory Affairs | 2009–2015 | Led Acthar Gel label modernization and FDA approval in Infantile Spasms; built regulatory, safety, and clinical quality groups |
| Promet Therapeutics, LLC | Co-Founder, Director & Chief Development Officer | Not disclosed | Co-founded; development leadership prior to joining Processa |
| AGI Therapeutics, plc | VP, Clinical & Regulatory Affairs (U.S.) | Not disclosed | Led global Phase 3 study execution and regulatory interactions |
| ICON plc – Strategic Drug Development Division | VP, Regulatory Affairs | Not disclosed | Senior regulatory leadership in CRO environment |
| GloboMax LLC (acquired by ICON) | Regulatory/Operations/Project Mgmt roles | Not disclosed | Regulatory and operational leadership at specialized FDA development CRO |
| University of Maryland School of Pharmacy | Clinical scientist/instructor; PK/biopharm lab | Not disclosed | Contributed to FDA-funded Clinical Pharmacology/UMAB-FDA contracts; instructor for FDA reviewers |
| Independent Consulting | Regulatory & development consultant | Not disclosed | Expert team member for multiple small/mid pharma companies |
External Roles
No public company directorships or external board roles disclosed for Dr. Bigora .
Fixed Compensation
| Metric | 2023 | 2024 |
|---|---|---|
| Base Salary ($) | $160,200 | $290,940 (incl. $11,664 deferred) |
| Target Bonus (%) | Not disclosed | Not disclosed (see 2025 employment terms below) |
| Actual Bonus Paid ($) | — | — |
| Stock Awards ($) | $136,837 | $14,484 |
| All Other Compensation ($) | $24,665 | $22,827 |
| Total ($) | $321,702 | $328,251 |
Notes:
- 2024: Executives voluntarily deferred salary; Dr. Bigora deferred $11,664 .
Performance Compensation
| Grant Date | Incentive Type | Metric | Target | Actual | Payout | Vesting |
|---|---|---|---|---|---|---|
| 06/28/2024 | RSUs (3,233 sh) | Service-based | Service to Jan 1, 2025 | Met | 3,233 sh | Vests 01/01/2025 |
| 06/28/2024 | RSUs (2,425 sh) | Service-based | Time-in-service | In progress | 2,425 sh | 1/3 on 01/01/2025; remainder monthly thereafter |
| 06/28/2024 | RSUs (404 sh) | Nasdaq compliance | Regain min price requirement | Met | 404 sh | Vested upon grant tied to compliance |
| 06/28/2024 | RSUs (404 sh) | Clinical milestone | First patient dosed in NGC‑Cap Phase 2 | Met | 404 sh | Vested on 10/02/2024 upon dosing |
| 01/01/2023 | RSUs (1,616 sh) | Service-based | Annual time-based | Partial | 1/3 each Jan 1, 2024–2026 | Vests 01/01/2024–2026 |
| 07/01/2021 | RSUs (215 sh) | Capital raise | Cumulative ≥$30M financing | Not yet disclosed | 215 sh | Vests upon $30M cumulative raise |